Gilead Sciences exercised an option to exclusively license KT-200, an oral CDK2 molecular glue degrader program developed by Kymera Therapeutics. The move expands Gilead’s strategy in targeted protein degradation, where CDK2 is a relevant cell-cycle axis. KT-200 was identified and characterized under a prior strategic collaboration between the two companies. For Gilead, the license adds to a growing portfolio built around protein degradation modalities. For Kymera, the deal provides commercial validation and reinforces the continued industry migration toward molecular glue and degradation approaches as differentiated mechanisms for oncology and beyond.